Figure S1: Study flow chart according to the international STARD guidelines. A total of 162 participants were potential included from whom 13 HCC patients were excluded due to therapy. Finally, 149 participants were included with 50 HCC patients, 49 liver cirrhosis patients, and 50 healthy subjects served as controls.